Clinical trial
A Dose-Ranging Safety, Tolerability, and Exploratory Efficacy Study of Adjunctive EQU-001 for Seizures in Adults With Epilepsy
NCT05063877 is registered in ClinicalTrials.gov with Equilibre Biopharmaceuticals B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Dose-Ranging Safety, Tolerability, and Exploratory Efficacy Study of Adjunctive EQU-001 for Seizures in Adults With Epilepsy
- Lead sponsor
- Equilibre Biopharmaceuticals B.V.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 31, 2021
- Completion date
- October 11, 2023
- Enrollment
- 43 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.